499 The impact of sustained virological response (SVR) on health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC) and persistently normal ALT levels (PNALT) treated with peginterferon alfa-2A (PEGASYS®) and ribavirin (COPEGUS®)

Abstract
No abstract available